trials
Hematopoietic SCT (HCT) outcomes are influenced by many patient-and disease-related factors such as age, disease stage and prior treatment, as well as transplantrelated factors such as stem cell source and transplant regimen. Ideally, most transplant strategies would be evaluated by large randomized clinical trials. However, various factors limit the application of randomized trials in this setting. Many diseases treated with transplantation are uncommon; single centers may treat few patients with a given disorder. This makes randomized trials difficult and limits the ability to perform nonrandomized trials with sufficient power to detect meaningful effects. Some important transplant issues are not amenable to randomization, such as impact of donor type. Most clinical trials focus on short-and intermediate-term outcomes (1-5 years). However, there is a need for long-term follow-up of transplant recipients, as some important problems, such as therapy-related cancers, may not occur until many years after treatment. Observational databases, such as those maintained by the CIBMTR and the European Blood and Marrow Transplant Group (EBMT), play an important role in facilitating research into these issues.
The CIBMTR was formed in 2004 through an affiliation of the International Bone Marrow Transplant Registry (established in 1972) and the research arm of the National Marrow Donor Program (NMDP, established in 1987) . The CIBMTR maintains a large database of clinical information on the outcome of BMTs performed in 450 transplant centers in 47 countries. The database includes information on more than 240 000 transplant recipients and registers about 14 000 new transplants yearly. Data quality and consecutive registration are ensured through extensive computer checks and on-site audits. A new web-based data entry program, FormsNet2.0, is currently being deployed to enhance data collection efforts and, eventually, to provide tools for centers to receive back and analyze their own data. FormsNet2.0 will interface with another CIBMTR/NMDP effort, AGNIS, which is a software application designed to facilitate the exchange of clinical HCT data directly from local databases. AGNIS will also provide a tool for the exchange of clinical data between international registries.
CIBMTR transplant centers are asked to provide yearly follow-up on survivors. The database includes information on 9000 survivors followed for 10 or more years. Additionally, pretransplant paired samples of cells and/or DNA are available for about 20 000 unrelated donorrecipient pairs; collection of samples from related donorrecipient pairs began in late 2007. Both data and biologic specimens are available to investigators for research. The CIBMTR has a staff of 5 PhD statisticians, 12 MS statisticians and 8 MD, MS Scientific Directors who support clinical investigators in designing, implementing and completing clinical studies. The CIBMTR PhD faculty also have an active methodological research program focused on identifying and developing optimal statistical approaches for HCT-related analysis.
Observational databases similar to that maintained by the CIBMTR may facilitate an understanding of transplant outcomes by addressing questions difficult to address in randomized trials. These include descriptions of transplant results in specific patient groups, analysis of prognostic factors, evaluation of new transplant regimens, comparison of transplant with nontransplant therapy, defining intercenter variability in practice and outcome, and developing innovative analytical approaches. Linking with other epidemiological data can provide insights into the availability and economics of HCT. Linking clinical data with immunological and genetic information can provide important insights into transplant biology.
Clinical databases may also aid the development of optimal designs for prospective clinical trials. Registry data can focus clinical trial efforts on areas most likely to be productive by providing preliminary data on the use and efficacy of developing therapeutic strategies. They allow trial planners to make more precise estimates of outcomes and accrual patterns, which can aid sample size calculations and implementation plans. The identification of appropriate centers for specific trials can increase efficiency. Information about the most commonly used supportive care measures can be used to adapt protocols to standard practices and thus increase their acceptability in the transplant community. Failure to accrue can be systematically addressed by studying characteristics (and alternative treatment) of patients potentially eligible but not enrolled. Comparison of clinical trials outcomes with observational outcomes can give insight about generalizability and patient selection practices. The use of the CIBMTR database is an integral part of the trial planning process of the US Blood and Marrow Transplant Clinical Trials Network (BMT CTN). The BMT CTN is a cooperative trial network established in 2001 by the US National Heart Lung and Blood Institute and the National Cancer Institute to perform multicenter clinical trials addressing important issues in BMT. Although the network has 16 core clinical centers/consortia, more than 65 centers have participated in BMT CTN trials. The CIBMTR, the National Marrow Donor Program (NMDP) and the EMMES Corporation collaborate to serve as the Network's Data and Coordinating Center. The BMT CTN has accrued about 2200 patients to 12 protocols to date. It recently organized a State of the Science Symposium, which included international experts in HCT, hematology and oncology, to achieve consensus on its scientific agenda for the next 5 years.
The establishment of international outcomes registries, leveraging their resources to facilitate clinical trials, and multicenter collaboration on both observational and interventional studies were important components of the advances in HCT over the past three decades, building on key laboratory discoveries and single center translational studies. Future progress will be further enhanced by inter-registry collaboration through Worldwide Blood and Marrow Transplant Group (WBMT).
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